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Abstract—Copy number aberrations (CNAs) are frequently
found in cancer genomes and believed to be tumorigenic.
Unfortunately, CNAs often occur in wide regions of the cancer
genome that harbor a large number of genes, making it a
challenge to identify the candidate cancer drivers. Further,
subtypes of cancer may be characterized with distinct CNA
patterns and hence have different drivers.
Here, we report a systematic method to automate the identi-
fication of candidate drivers in cancer subtypes. Specifically, we
propose an iterative approach that alternates between kernel
based gene expression clustering and gene signature selection.
We applied the method to datasets of the pediatric cancer
medulloblastoma (MB). A cross-dataset comparison indicates
the robustness of our subtyping method.
Based on the identified subtypes, we developed a PCA based
approach for subtype-specific identification of cancer drivers.
The top-ranked driver candidates are found to be enriched
with known pathways in certain subtypes of MB. This might
reveal new understandings for these subtypes.
Keywords-copy number aberration (CNA); medulloblastoma;
cancer subtypes; driver identification
I. INTRODUCTION
Cancers are initiated and driven by aberrant genetic events
(a.k.a. hits), such as copy number aberrations (CNAs), called
the drivers of cancer. Further, quite a few cancers, such
as breast cancer [1], glioblastoma [2] and medulloblastoma
[3], are believed to contain subtypes, each with distinct
molecular profiles and clinical outcomes. Different subtypes
may have arisen because of different mechanisms, such as
the hits on different pathways and/or different cells-of-origin
[4] within the same tissue/organ. Stratifying the patients into
appropriate subtypes is the key to uncover the drivers of
these mechanisms.
There is a plethora of literature dedicated to the develop-
ment of supervised [5], semi-supervised [6] or unsupervised
[7] approaches for the discovery of classes within a cancer
dataset. However, there are major differences between class
discovery and cancer subtyping:
∙ The levels of data for analysis are different. In class
discovery, typically one level of data (e.g., gene ex-
pression data, copy numbers/sequencing data or clinical
data) is used, whereas in subtyping, a combination of
these datasets may need to be considered. The reason
is that the establishment of a cancer subtype requires
evidences at various levels of behaviors.
∙ The objectives of features selection are different. While
feature selection algorithms such as SVM-RFE [8]
attempt to find a subset of genes with maximal pre-
dictive power; to ensure the functional interpretability,
the feature selection criteria in subtyping also include
the subtype-specificity of selected genes (i.e., gene
signature).
On the other hand, the subtypes and corresponding signa-
ture thus identified may shed light on the subtype-specific
cancerous process. Also, genetic aberrations enriched in a
particular subtype may be related to, or even have causing
roles in these processes. Particularly, one type of genetic
events, CNA, is widely found in the cancer genomes [9] and
they occur at the DNA level, which is on the upper stream of
gene expressions as dictated by the central dogma of biology.
CNAs are also found to be positively correlated with the raw
expressions of affected genes [3]. In some cancer, such as
medulloblastoma, the CNA patterns are also found to be
subtype-dependent [10].
However, given the large number of CNA-affected genes
that often occur within a cancer genome, it is not practical
to assume that all of them are tumorigenic. Instead, most
of the CNAs may just cause mechanic responses in the
affected genes’ expressions, but otherwise not involve in
the cancerous process. Apart from these, a small proportion
of CNAs may have involved in the initiating, driving or
sustaining of the cancerous process, that gives rise to the
subtype-specific signature.
Fig. 1 summarizes the machinery of CNA-induced can-
cerous process inside a subtype. From the figure, the gene
signature may reflect underlying processes characterizing
individual subtypes. Therefore, performing cancer subtyping
by signature selection may be closer to the definition of
’subtype’ and help unveil the common mechanism within a
subtype.
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Figure 1. The role of CNAs in cancer, subtypes and clustering of
expression data.
Towards this end, we propose an integrative approach to
perform subtyping based on gene expressions and driver-
identification based on CNA measurements (e.g., SNP ar-
rays). This paper is organized as below. Sections II and
III discuss the gene-signature based iterative subtyping ap-
proach and the PCA based driver identification, respectively.
In Section IV, we apply the algorithm to datasets of a can-
cer, medulloblastoma, and compare our findings with other
methods. Section V discusses the results of the algorithms.
II. THE SUBTYPING ALGORITHM
As described above, gene expression signature underpins
the biological processes, and is usually enriched in known
canonical pathways, and hence using it for subtyping may
be more accurate than by geometric clustering. We therefore
propose to integrate signature detection into the subtyping
process. A general framework is proposed as below:
1. Given an expression dataset 𝐸 = {𝐸𝑖,𝑗 ∣𝑖 = 1..𝑁, 𝑗 =
1..𝐽} with 𝑁 samples and 𝐽 genes, select an initial set of
genes, Φ, say the top 10% of genes with largest variances,
to yield a reduced dataset ?ˆ? = {𝐸𝑖,𝑗 ∣𝑗 ∈ Φ}.
2. Perform clustering on ?ˆ?.
3. Determine the number (say, 𝐾) of clusters in ?ˆ?, and
divide the samples into 𝐾 subgroups.
4. Detect the subtype-specific DEGs using the original
dataset 𝐸, i.e., signature 𝑆𝑘, for each subtype 𝑘 ∈
{1, ..,𝐾}.
5. Update Φ using the new gene set Φ = 𝑆1∪, ..,∪𝑆𝐾 .
6. Update ?ˆ? with the new set of signature genes Φ.
7. Repeat Steps 2 to 6, till certain convergence criterion,
(e.g. stability of the signature genes) is reached.
To implement the above framework, there are a few issues
to address:
∙ The existence of outliers. Most subtyping methods are
extremely sensitive to outliers. These samples may be
because of rare disease mechanisms, noisy measure-
ments or mislabeling of samples, etc.
∙ The clustering metric. As compared with Euclidean
distance in the linear space, principal component (PC)
based and kernelized distance metric puts stronger em-
phasis on the localized information of a set of samples.
This is particularly useful in unveiling the underlying
topology of a dataset.
∙ Determining the number of subtypes. This is an open
challenge in unsupervised learning and cancer subtyp-
ing. For example, in medulloblastoma, recent works had
estimated the number of subtypes at four [11], five [3]
and six [10], and receive almost equal acceptance. This
makes cross-study comparison difficult.
∙ Gene signature detection. Detection of DEGs in the
two-class or even multiple-class scenarios has been
extensively explored [12], [13]. However, there has not
been much emphasis on the subtype-specificity of these
measures.
The following subsections discuss the solutions to these
problems.
A. Outlier (Marginal Sample) Detection
In this paper we use methods that are generally used in
outlier detections to detect marginal samples. It is assumed
that marginal samples lie in sparse regions, i.e., a sample is
said to be marginal if it is on average much further away
from its neighbors than would be core samples. We adopt
a heuristic proximity-based approach, i.e., the 𝑘-NN based
algorithm [14]. Let 𝜈 be the average distance of all the
samples to their centroid, i.e., 𝜈 =
∑
𝑖 ∥𝑒𝑖 − 𝑒∥ /𝑁 , where
𝑒𝑖 = [𝐸𝑖,1, .., 𝐸𝑖,𝐽 ]
𝑇 and 𝑒 =
∑
𝑖 𝑒𝑖/𝑁 . A sample is said
to be marginal if the average distance of this sample to its
𝑛 closest neighbors, called score of marginality (SMar), is
greater than 𝑝𝜈 , where 𝑝 is a user-specified scaling factor.
Consequently, the detected marginal samples are retained
for testing and the remaining samples (i.e., core samples)
are used for training.
B. Clustering and Determining the Number of Clusters
There are many unsupervised techniques that can be used
for clustering, such as the heuristic-based 𝑘-means [15],
the topology-based self-organizing map [16], non-negative
matrix factorization [7], etc. A major problem in cancer
subtyping is that in different subtypes, different pathways
or processes might have been turned on or off and the
resulting DEGs may be under very different degrees of
regulation. As a result, in the gene expression space, samples
of certain subtypes may tightly disperse in a constrained
space, whereas samples of other subtypes may loosely
occupy another space. That is, different subtypes may have
different densities of samples in the gene expression space.
Algorithms such as hierarchical clustering (HC) [17] tend
to cluster the densely populated space before joining the
sparsely populated space. As a result, class boundaries
obscure. And cluster boundary determination by a uniform
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threshold on the joining heights of dendrograms could be
error-prone [18]. The situation worsens if the numbers of
samples in the subtypes are highly imbalanced.
To tackle these, we employ two strategies:
∙ Performing clustering in the topological space. Such
techniques use the inter-sample distances as a new met-
ric and penalize long distances by subjecting them to a
(e.g. Gaussian) kernel. The resulting datasets represent
localized information of individual samples.
∙ Using a one-cluster-at-a-time method. The first cluster
is detected and removed before the remaining data are
used for further detection. The algorithm terminates if
no further cluster can be found.
Specifically, given a dataset ?ˆ? = [𝑒1, .., 𝑒𝑁 ]𝑇 , the following
steps are taken (cf. [19]):
a. Construct an affinity matrix 𝐴 such that 𝐴𝑖,𝑗 =
exp(−∥𝑒𝑖 − 𝑒𝑗∥2/2𝜎2), ∀𝑖 ∕= 𝑗, otherwise 𝐴𝑖,𝑗 = 0.
b. Form the matrix 𝐿 = 𝐷−1/2𝐴𝐷−1/2, where 𝐷 is a
diagonal matrix with 𝐷𝑖,𝑖 =
∑
𝑗 𝐴𝑖,𝑗 .
c. Obtain the top 𝑘 eigenvectors 𝑋 = [𝑥1, .., 𝑥𝑘] ∈ ℜ𝑁×𝑘
of 𝐿 with largest eigenvalues. Empirically, 𝑘 can be
determined by the maximum number 𝑘 such that the
ratio between the 𝑘th eigenvalue and the first one remains
above certain threshold (0.05, say).
d. Use the rows of 𝑋 to perform clustering and construct a
dendrogram.
e. Starting from the root of the dendrogram, check if a split
is necessary by the gap-statistic [20]. If the resulting split
results in significant drop of within-cluster variance, the
dendrogram should be split into two trees.
f. Proceed the check recursively in the resulting trees in
a breadth-first manner. If a resulting tree contains no
significant splittable clusters or if the tree contains only
a few samples, the tree itself becomes a cluster and is
removed.
g. Carry on the above step till all resulting trees are exam-
ined.
h. Perform gene-signature detection for the resulting clus-
ters. And conduct a pair-wise comparison on the gene
signatures of all clusters. Merge two clusters if their gene
signatures are similar.
C. Gene Signature Detection
A subtype signature is defined to be the set of genes whose
expressions are either significantly up- or down-regulated in
a subtype, as compared with those of all other subtypes,
which may also include the normal samples. To identify
the subtype signatures, a three step algorithm is developed:
(i) detection of differentially expressed genes (DEGs), (ii)
detection of subtype-specific DEGs, or subtype signature,
and (iii) ranking of genes within a subtype signature.
To detect the DEGs, given expressions
𝑦𝑗 = [𝐸1,𝑗 , .., 𝐸𝑁,𝑗 ] for gene 𝑗 and the subtyping
result, an ANOVA is performed to test: 𝐻0 : 𝜇𝑗1 = .. = 𝜇
𝑗
𝐾
, where 𝜇𝑗𝑘 is the mean of the within-subtype mean of
gene 𝑗 for subtype 𝑘. To account for the large number of
comparisons, we use the family-wise error rate (FWER) as
corrected by the Holm-Bonferroni [21] method to select the
top DEGs.
In a multiclass setting, subtype-specific DEGs can be de-
tected via post-hoc analysis. For each of the DEGs detected
in the ANOVA, Tukey’s honest significance test (TukeyHSD)
[22] is followed to conduct a pair-wise comparison of its
expression in one subtype with that in another. A DEG is
said to be specific to a subtype, if the TukeyHSD signs of
it in that subtype’s comparisons with all other subtypes are
identical, i.e., all positive or all negative, and the correspond-
ing adjusted 𝑝-values are all significant. It is worth noting
that no restrictions are imposed on other adjusted 𝑝-values
in the TukeyHSD test, which allows for slight inter-subtype
variations in the non-specific subtypes.
Finally, a ranking of each subtype’s specific genes is
needed to provide an order of functional relevance for these
genes. To this end, for each subtype, a comparison for
each of the detected signature genes in this subtype, against
all other samples as a group, is performed. The subtype
signature genes are ordered according to their corresponding
𝑝-values. LIMMA [13] with BH [23] false discovery rate
(FDR) control is applied in this step. At the end of these
steps, we obtain a set of ranked signature genes 𝑆𝑘 for
subtype 𝑘.
III. THE SUBTYPE-SPECIFIC DRIVER
IDENTIFICATION ALGORITHM
According to Fig. 1, even within a subtype, there could
be different driving events. Here, we focus on the dominant
subtype-specific events, i.e., CNAs. CNAs often occur on a
broad region in the cancer genome and presumably harbor
far more genes than necessary to trigger cancer. As a result
of the efficient responses from CNAs, most of which may
be mechanic but otherwise non-cancerous, the search for
candidate CNAs that might be responsible for the cancerous
process becomes challenging (cf. Fig. 1). Nevertheless, the
subtype-specific DEGs, i.e., gene signature, offer a retro-
spective clue for subtype-specific driver identification.
A CNA-affected gene can activate the cancerous process
through its CNA-induced aberrant expressions. Therefore,
its expression may likely be correlated with the signature
genes, which are believed to be the consequences of subtype-
specific processes.
To identify the drivers, for a subtype 𝑘 and its signature
𝑆𝑘 (∣𝑆𝑘∣ ≜ 𝑀 ), and 𝐿 candidate CNA genes, an 𝑀 -by-
𝐿 matrix 𝑍𝑘 of pair-wise Pearson correlation coefficients
between the signature genes and the expressions of the CNA
genes is computed, using the within-subtype samples only.
We may assume that a row-wise zero-meaned operation has
been applied to 𝑍𝑘. A PCA approach can next be applied
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to determine the correlation of each CNA with the set 𝑆𝑘,
as follows:
a. Perform an SVD: 𝑍𝑘 = 𝑈Σ𝑉 𝑇 , and then project 𝑍𝑘 onto
the first principle vector 𝑢1 of 𝑈 , to give 𝑧1 = 𝑢𝑇1 𝑍𝑘. The
individual entry of 𝑧1 represents the overall correlation
of each CNA gene with the set of signature genes.
b. For a candidate CNA gene 𝑙 ∈ {1, .., 𝐿}, the more
positive 𝑧𝑙1 is, the more gene 𝑙 is positively correlated with
𝑆𝑘, and vice versa. Therefore, the values of 𝑧1 provide a
ranking for the candidate CNA genes.
c. The 𝑝-values of 𝑧1 can be obtained by generating a
random set of signature genes and repeating the above
procedure to produce a null distribution for 𝑧1. The
candidate drivers can then be ranked by their 𝑝-values.
The set of candidate CNA genes can be obtained by
finding the set of significantly recurrent CNAs in subtype
𝑘 via GISTIC [24] using the SNP arrays matching to the
samples in 𝑘.
IV. RESULTS AND DISCUSSION
To implement the proposed approach, we applied it to
medulloblastoma (MB) datasets. MB is a pediatric brain
tumor that usually affects children below the age of 15.
The overall five-year survival rate for MB-affected children
is poor (around 50% [25]) and varies a lot from patient
to patient, subject to different predisposition conditions.
Integrative genomic studies [3], [10] in recent years have
attempted to classify MB patients into various numbers of
subtypes, two of which are well-accepted, namely, the Wnt-
and Shh-pathway associated subtypes, respectively. For the
remaining non-Wnt/non-Shh patients, there are still debates
on whether to characterize them as a single or multiple
subtypes.
Two publicly available medulloblastoma datasets were
used. The first dataset consists of 76 primary MB samples
by Cho et al. [10]. The second dataset consists of 62 primary
MB samples from Kool et al. [3] (GEO accession number:
GSE10327). For convenience, the two datasets are referred
to as 𝒟1 and 𝒟2, respectively. Note that 𝒟2 uses a newer
gene expression array and contains more probesets than 𝒟1.
For simplicity, only probesets common to both 𝒟1 and 𝒟2
are used.
A. Subtyping Result
The proposed score of marginality (SMar) in Section II
was first applied to both datasets. Fig. 4A-B shows the
result of this step. Ultimately, 75 and 60 core samples are
identified in 𝒟1 and 𝒟2, respectively. These core samples are
separately trained with the proposed subtyping algorithm.
The application to 𝒟1 terminates with three clusters as in
Fig. 4C. When applying to 𝒟2, the algorithm makes three
splits before it finds that the third splits (the ∗ mark in
Fig. 4D) results in child trees that are almost identical in
gene signatures (85.67% overlap, compared with only 2.42%
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Figure 2. Subtyping results. A. Our marginal sample detection algorithm
detects one outlier in 𝒟1 and; B. two outliers in 𝒟2. C. The dendrogram of
𝒟1. D. The dendrogram of 𝒟2. The crosses represent splitting decisions by
the algorithm. The ∗ represents a considering split that is later abandoned
because of the similarity of the resulting trees’ signatures.
Table I
CROSS-DATASET COMPARISON OF SUBTYPE SIGNATURES
Subtypes of 𝒟2
Subtypes of 𝒟1 a b c # of 𝒟1 signatures
A 298 12 4 504
B 12 132 5 266
C 2 5 132 345
# of 𝒟2 signatures 548 286 224
overlap between Subtype A and C). Therefore, a decision
was made to merge the two clusters into one subtype.
Finally, the algorithm puts the estimates of numbers of
subtypes to be three in both datasets. For convenience, the
three subtypes of 𝒟1 are denoted as A, B and C, respectively;
and those of 𝒟2 are denoted as a, b and c, respectively.
The signatures of individual subtypes in both datasets and
their pairwise overlaps are shown in Table I. Obviously,
Subtype A in 𝒟1 corresponds to Subtype a in 𝒟2, and so
forth. Fig. 3 shows some top-ranked signature genes for
individual subtypes. It is not hard to see that Subtype A
Table II
CROSS-DATASET VALIDATION OF SUBTYPING RESULT BY OUR METHOD
𝒟2
𝒟1 a b c outliers Row Total
A 9∗(7†) 0 (0) 0 (0) 9 (7)
B 0 (0) 13 (17) 0 (0) 13 (17)
C 0 (0) 0 (1) 38 (50) 2 40 (51)
outliers (1) (1)
Column Total 9 (7) 13 (19) 38 (50) 2 62 (76)
∗ Numbers outside brackets represent samples in 𝒟2 predicted to be a
subtype in 𝒟1.† Numbers inside brackets represent samples in 𝒟1 predicted to be a subtype
in 𝒟2.
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Figure 3. Examples of gene signatures for individual subtypes in 𝒟2. A,
example signature genes in Subtype A. B, for Subtype B. C, for Subtype
C. Within each plot, the three boxplots refer to expressions of a gene in
the three subtypes, respectively.
Table III
NUMBERS OF CANDIDATE CNAS WITHIN EACH SUBTYPE
Subtype A Subtype B Subtype C
gains losses gains losses gains losses
# genes 0 359 0 281 692 561
is characterized with Wnt-pathway genes, Subtype B with
Shh-pathway genes, etc. Hence, Subtype A and B are the
Wnt and Shh subtypes, respectively.
To conduct a cross-dataset validation, we used the gene
signatures and trained cluster membership in 𝒟1 to predict
the cluster membership in 𝒟2, and vice versa. Table II lists
the result. It can be seen that all but one sample in 𝒟1 are
predicted with class labels that correctly match their trained
labels. The outlier in 𝒟1 is predicted to be Subtype B, while
the two outliers in 𝒟2 are both predicted to be Subtype C.
B. Driver Identification Result
Copy number measurements via SNP arrays of 𝒟1
were processed and submitted to GISTIC (via genepat-
tern.broadinstitute.org) for detection of recurrent CNAs
within each subtype. The results of this pre-selection step
are listed in Table III.
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Figure 4. Null distributions (black curves) and 𝑧1 (red curves) for the
three subtypes. A, Subtype A. B, Subtype B. C, Subtype C.
As described in Section III, within-subtype correlations
between the pre-selected CNAs and the gene signature were
then conducted and the PCA-based ranking method was
applied. The projected vector 𝑧1 and the null distributions are
shown in Fig. 4. Note that in Subtype A, the CNA genes tend
to be negatively correlated with the gene signature, whereas
those in Subtypes B&C tend to be positively correlated. This
is perhaps because of the predominant deletion patterns of
Chr6 in Subtype A.
Table IV shows the top-ranked (𝑝-value < 0.01) candidate
drivers in each subtype. Of note, all three subtypes contain
some genes that seem to suggest the underlying pathways
that characterize the subtypes. For example, Subtype A
candidate drivers include MAP3K7, which has inhibiting
roles in the Wnt-pathway [26]. Its deletion might cause
the difficulty to inactivate Wnt-pathway and results in a
persistently activating Wnt-pathway. Further, TULP4 is re-
cently identified as a candidate suppressor gene in the Wnt-
associating subtype [27]. The top candidate driver in Subtype
B, PTCH1, is a key gene in the Shh-pathway. Its deletion
may result in the inability to inhibit Smoothened, and
activate Shh permanently. Indeed, mutations in PTCH1 have
been one of the top targets in recent literature attempting to
find predisposition loci for MB [28]. Perhaps of most interest
is the Wnt-associating genes, such as FZD1, PPP3CB and
NLK, that are found in Subtype C. As compared with Wnt-
and Shh-subtypes, the gene signature of this subgroup of MB
does not seem to be significantly enriched with any canonical
pathways. The candidate drivers that significantly correlate
with the signature genes here seem to suggest that some
Wnt-pathway activities are involved in Subtype C; although
the exact roles of Wnt have yet to be clarified, as both NLK
and FZD1 are amplified but the former has inhibiting while
the latter has promoting roles.
V. CONCLUSION
In this work, a two-step algorithmic framework is de-
veloped to perform gene-signature based cancer subtyping
and to identify subtype-specific CNAs drivers. The algo-
rithm was applied to datasets of medulloblastoma, producing
dataset-invariant subtyping results. The driver identification
results were found to be enriched with cancer-driving path-
ways. This study has contributions in several aspects.
First, a subtyping technique depending on the signature-
based clustering addresses quite a few issues in unsupervised
learning of cancer datasets. Particularly, the emphasis on
subtype-specificity for gene signature detection allows for
functional interpretation of the cancerous process or path-
ways underlying each subtype.
Second, subtype-specific driver identification provides an
efficient algorithm to relate the dysregulated pathway activi-
ties to the aberrations at the DNA level. Its capability to rank
such candidates provides a way to automate the process of
driver identification.
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Table IV
CANDIDATE CNA DRIVERS WITHIN EACH SUBTYPE
Subtype A (FDR: 0.033) Subtype B (FDR: 0.095) Subtype C (FDR: 0.058)
Significant
candidate
drivers
NRN1, SOX4, NUP153, FAM8A1, C6orf62, MRS2, BTN2A1,
ZNF193, ZNF187, BAT3, C6orf134, ZNF318, UBR2,
KIAA0240, CDC5L, MUT, ICK, FBXO9, PTP4A1, SMAP1,
SLC35A1, RNGTT, SNAP91, MAP3K7, IBTK, SFRS18,
ZNF292, PHIP, DOPEY1, SYNCRIP, CASP8AP2, MARCKS,
HDAC2, ASF1A, FOXO3, HSF2, CDC2L6, TSPYL4, MED23,
TRMT11, FAM184A, CCDC28A, HECA, AHI1, RBM16,
TULP4, TCP1, TBP
PTCH1, SLC35D2,
ANGPTL2, TRPM3,
UGCG, ALAD, HDHD3,
STOM, ASTN2,
RABGAP1, GOLGA1,
AK1, SPTAN1, DNM1,
BAT2L, NPLOC4
PDGFA, SRI, PCOLCE, EPHB4, TRIP6,
SYPL1, MDFIC, MAP2K6, GPRC5C,
NAV2, AHNAK, GNG3, GPR56, MAF,
PMP22, IQCE, CHN2, POM121,
GTF2IRD1, PCLO, FZD1, AKAP9,
PSMD11, NLK, RHOT1, ACLY, MPP3,
CBX1, MMD, HEATR6, MED13, KCNJ2,
TEX2, PPP3CB, DLG5, CHD3
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